Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: Evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism

@article{Bhamidipati2005PreclinicalAO,
  title={Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: Evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism},
  author={R. Bhamidipati and S. Mujeeb and P. Dravid and A. A. Khan and S. Singh and Y. Rao and R. Mullangi and N. Srinivas},
  journal={Xenobiotica},
  year={2005},
  volume={35},
  pages={253 - 271}
}
  • R. Bhamidipati, S. Mujeeb, +5 authors N. Srinivas
  • Published 2005
  • Chemistry, Medicine
  • Xenobiotica
    • The aim of this study was to characterize the pharmacokinetics and determine the absolute bioavailability and metabolism of DRF 4367, a novel COX-2 inhibitor, in mice. In addition, the in vitro metabolism of DRF 4367 was studied in mouse, rat, dog, monkey and human liver microsomes. Following oral administration, maximum concentrations of DRF 4367 were achieved after about 1 h. Upon intravenous (IV) administration, the concentration of DRF 4367 declined in a bi-exponential fashion with a… CONTINUE READING
    View on Taylor & Francis
    cypex.co.uk
    8 Citations
    8 Citations
    Citation Type

    Citation Type

    Study on pharmacokinetics and tissue distribution of the isocorydine derivative (AICD) in rats by HPLC-DAD method
    • 1
    Glucuronidation of DRF-6574, hydroxy metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes and recombinant human UDP-glucuronosyltransferases (UGT): Role of UGT1A1,1A3 and 1A8
    • 3
    In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A.
    • 37
    • PDF
    Preclinical pharmacokinetics, tissue distribution and excretion studies of a potential analgesics - corydaline using an ultra performance liquid chromatography-tandem mass spectrometry.
    • 13
    Identification of 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl]-N-propionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration.
    • 3
    Application of a liquid chromatography-tandem mass spectrometry method to the pharmacokinetics, tissue distribution and excretion studies of Dactylicapnos scandens in rats.
    • C. Guo, Y. Jiang, +9 authors S. Zeng
    • Chemistry, Medicine
    • Journal of pharmaceutical and biomedical analysis
    • 2013
    • 18
    N-acylated sulfonamide sodium salt: a prodrug of choice for the bifunctional 2-hydroxymethyl-4-(5-phenyl-3-trifluoromethyl-pyrazol-1-yl) benzenesulfonamide class of COX-2 inhibitors.
    • 11
    Regulation of metabolizing enzymes and transporters for drugs and bile salts in human and rat intestine and liver: a study with precision-cut slices
    • PDF

    References

    SHOWING 1-10 OF 32 REFERENCES
    The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
    • 77
    • PDF
    Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice.
    • 33
    • PDF
    The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects.
    • 43
    • PDF
    Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers.
    • 76
    Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats.
    • 135
    • PDF
    Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.
    • 71
    • PDF
    Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human.
    • 50
    • PDF
    HPLC method for determination of DRF-4367 in rat plasma: validation and its application to pharmacokinetics in Wistar rats.
    • 2
    In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).
    • 43
    • Highly Influential
    Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: identification of active metabolites.
    • 15
    • Highly Influential
    • PDF